Article and Video CATEGORIES
Denise has over 30 years of varying experience in the healthcare arena. In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees. She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.
Have you received a diagnosis of ovarian cancer?
GRACE is excited to have again partnered with Clinical Care Options to develop an Interactive Decision Support Tool and downloadable resource to help you understand more about your disease and treatment options, so you can become partners with your oncology team in your cancer care.
By answering multiple choice questions about your diagnosis, you will be able to review treatment options from five ovarian cancer experts listed below.
-
Robert L. Coleman, MD, FACOG, FACS Texas Oncology
- Thomas J. Herzog, MD UC Health
- Ursula Matulonis, MD Dana Farber/Harvard Cancer Center
- Bradley J. Monk, MD, FACOG, FACS Arizona Oncology
- Kathleen Moore, MD Stephenson Cancer Center
Clinical Care Options LLC, is a global leader in the development of innovative educational programs and technology platforms. GRACE is pleased to work with CCO on a number of patient materials and tools to help our community in their cancer journey.
The following list of decision support tools are available on our GRACE and Clinical Care Options Patient Tools partner page:
-
Treatment Options From 5 Experts for Patients With Ovarian Cancer
-
Expert Insights Interactive Decision Support Tool for Advanced NSCLC
-
Information Regarding Immune Checkpoint Inhibitor Therapy
-
Educational Video - Immunotherapy for Advanced NSCLC: Discussing Goals and Treatments With Your Health Care Provider
-
Expert Insights Interactive Decision Support Tool on HER2+ Early Stage Breast Cancer
-
Expert Insights Interactive Decision Support Tool on Melanoma
-
Expert Insights Interactive Decision Support Tool for Frontline Follicular Lymphoma
-
Educational Videos -Measurable Residual Disease (MRD) in Acute Lymphocytic Leukemia (ALL)
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...
Recent Comments
That's…